Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | GLA | P06280 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31008679 | 0.97 | ALDH1A1 (0.30) | CYP2C19TSHRALDH1A1MEN1GLA | |
| SCHEMBL23638799 | 0.92 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL13924449 | 0.92 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL23139671 | 0.92 | LMNA (0.32) | — | |
| SCHEMBL27399450 | 0.89 | LMNA (0.42) | CYP2C19TSHRALDH1A1MEN1GLA | |
| SCHEMBL21278074 | 0.89 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL7107370 | 0.88 | — | — | |
| SCHEMBL8050403 | 0.87 | — | — | |
| SCHEMBL7952399 | 0.87 | TSHR (0.33) | TSHRALDH1A1 | |
| SCHEMBL24831752 | 0.87 | TSHR (0.48) | CYP2C19TSHRALDH1A1MEN1GLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260115648-A1 | Non-Triazine Based Scavengers | CHAMPIONX LLC (US) | 2026-04-30 | — | — | US | claimed |
| US-20260115648-A1 | Non-Triazine Based Scavengers | CHAMPIONX LLC (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090241-A1 | NON-TRIAZINE BASED SCAVENGERS | CHAMPIONX LLC (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3122789-B1 | 9,10-BIS(1,3-DITHIOL-2-YLIDENE)-9,10-DIHYDROANTHRACENE POLYMERS AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2019-05-08 | — | — | EP | disclosed |
| EP-2997613-B1 | REDOX FLOW CELL FOR STORING ELECTRICAL ENERGY AND USE THEREOF | Jenabatteries GmbH (DE) | 2017-11-22 | — | — | EP | disclosed |
| EP-2808021-B1 | BRAIN FUNCTION IMPROVING AGENT | UNIV TOHOKU (JP) | 2017-08-23 | — | — | EP | disclosed |
| EP-3114154-B1 | NEW TETRACYANO-ANTHRAQUINO-DIMETHANE POLYMERS AND USE THEREOF | EVONIK DEGUSSA GMBH (DE) | 2017-08-09 | — | — | EP | disclosed |
| EP-3122789-A1 | 9,10-BIS(1,3-DITHIOL-2-YLIDENE)-9,10-DIHYDROANTHRACENE POLYMERS AND USE THEREOF | Evonik Degussa GmbH (DE) | 2017-02-01 | — | — | EP | disclosed |
| EP-3114154-A1 | NEW TETRACYANO-ANTHRAQUINO-DIMETHANE POLYMERS AND USE THEREOF | Evonik Degussa GmbH (DE) | 2017-01-11 | — | — | EP | disclosed |
| EP-2439204-B1 | HETEROCYCLIC COMPOUND AND HEMATOPOIETIC STEM CELL AMPLIFIER | NISSAN CHEMICAL IND LTD (JP) | 2017-01-04 | — | — | EP | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| US-5763639-A | REACTION OF AMINE WITH (DI)ALDEHYDE, HYDROCYANIC ACID OR ALKALI METAL CYANIDE, QUATERNIZATION WITH ALKYLATING AGENT | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-09 | — | — | US | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0434316-A1 | Processes | ZENECA LIMITED (GB) | 1991-06-26 | — | — | EP | disclosed |
| US-4468526-A | Process for the preparation of thiuram disulfides | AKZONA INCORPORATED (US) | 1984-08-28 | — | — | US | disclosed |
| US-4459424-A | SECONDARY AMINE, CARBON DISULFIDE, METAL CONTAINING CATALYST | AKZONA INCORPORATED (US) | 1984-07-10 | — | — | US | disclosed |
| US-4113764-A | Manufacture of N-substituted glycinonitriles | BASF AKTIENGESELLSCHAFT (DE) | 1978-09-12 | — | — | US | disclosed |
| US-4022815-A | Manufacture of substituted glycinonitriles | BASF AKTIENGESELLSCHAFT (DT) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260115648-A1 | Non-Triazine Based Scavengers | CBS, TST, GSS | CYP2C19 3735/4885TSHR 1411/4885ALDH1A1 1085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.